H Farzadegan
Overview
Explore the profile of H Farzadegan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1819
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duggal P, An P, Beaty T, Strathdee S, Farzadegan H, Markham R, et al.
Genes Immun
. 2003 May;
4(4):245-50.
PMID: 12761559
CXCR6 is a chemokine receptor and the primary coreceptor in SIV infection. A single nucleotide polymorphism 1469G-->A, results in a nonconservative change in codon 3 (CXCR6-E3K) of the N-terminus of...
2.
Arnsten J, Demas P, Farzadegan H, Grant R, Gourevitch M, Chang C, et al.
Clin Infect Dis
. 2001 Sep;
33(8):1417-23.
PMID: 11550118
To compare electronically monitored (MEMS) with self-reported adherence in drug users, including the impact of adherence on HIV load, we conducted a 6-month observational study of 67 antiretroviral-experienced current and...
3.
Webber M, Schoenbaum E, Farzadegan H, Klein R
AIDS
. 2001 Aug;
15(11):1417-20.
PMID: 11504963
Objective: To assess the detection and quantitation of HIV-1 from tampon eluents in comparison with cervicovaginal lavage (CVL) and plasma specimens from the same women. Methods: Ninety-seven tampon, 105 CVL,...
4.
Shrestha S, Strathdee S, Brahmbhatt H, Farzadegan H, Vlahov D, Smith M
AIDS
. 2000 Sep;
14(11):1507-13.
PMID: 10983637
Objective: To develop laboratory methods to differentiate between single- versus multi-person use of syringes by injection drug users. Methods: Forensic short tandem repeat (STR) genetic analysis was undertaken to cross-validate...
5.
Shankarappa R, Margolick J, Gange S, Rodrigo A, Upchurch D, Farzadegan H, et al.
J Virol
. 1999 Nov;
73(12):10489-502.
PMID: 10559367
To understand the high variability of the asymptomatic interval between primary human immunodeficiency virus type 1 (HIV-1) infection and the development of AIDS, we studied the evolution of the C2-V5...
6.
Carneiro M, Yu X, Lyles C, Templeton A, Weisstein A, Safaeian M, et al.
J Infect Dis
. 1999 Sep;
180(4):1025-32.
PMID: 10479127
The effect of injection-drug use on human immunodeficiency virus type 1 (HIV-1) env genetic evolution was examined in 15 seroconverting injection-drug users followed up for 4 years. After adjustment for...
7.
Rompalo A, Astemborski J, Schoenbaum E, Schuman P, Carpenter C, Holmberg S, et al.
J Acquir Immune Defic Syndr Hum Retrovirol
. 1999 May;
20(5):448-54.
PMID: 10225226
Objectives: To compare the prevalence of HIV-related symptoms, physical examination findings, and hematologic variables among women whose risk for HIV is injection drug use since 1985 as opposed to sexual...
8.
Lyles C, Graham N, Astemborski J, Vlahov D, Margolick J, Saah A, et al.
Eur J Epidemiol
. 1999 Apr;
15(2):99-108.
PMID: 10204638
Cell-associated infectious HIV-1 viral load was measured using semi-quantitative microculture techniques to determine its predictive capability for progression to AIDS or survival among HIV-1 infected injecting drug users (IDU) and...
9.
Rinaldo Jr C, Gupta P, Huang X, Fan Z, Mullins J, Gange S, et al.
AIDS Res Hum Retroviruses
. 1998 Nov;
14(16):1423-33.
PMID: 9824320
We investigated memory cytotoxic T lymphocyte (CTLm) responses to HIV-1 as a determinant of HIV-1 disease progression, in relation to plasma HIV-1 load and T lymphocyte numbers in a longitudinal...
10.
Farzadegan H, Hoover D, Astemborski J, Lyles C, Margolick J, Markham R, et al.
Lancet
. 1998 Nov;
352(9139):1510-4.
PMID: 9820299
Background: Plasma HIV-1 RNA measurements are used for initiation of antiretroviral treatments. Whether the viral-load association with prognosis is similar in women and men is unknown. Methods: We studied 812...